Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
12:48pm, Friday, 10'th Feb 2023
Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
05:00pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.
Mind the Gap: Understanding the 3 Types of Price Gaps
01:40pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Large price gaps can mark the end of a major price moves or be the signature of a future winning stock. Andrew Rocco explains the difference through historical examples.
2 Biotech Stocks That Could Make You Richer
01:00pm, Thursday, 09'th Feb 2023 The Motley Fool
Patience will pay off with these two stocks.
Hedge Funds Love These 8 Dividend Blue Chips, And So Should You
12:15pm, Tuesday, 07'th Feb 2023 Seeking Alpha
Hedge funds employ some of the world's brightest analysts, with the most resources for analyzing companies. Find out 8 blue-chips that hedge funds love.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
11:20am, Tuesday, 07'th Feb 2023 Zacks Investment Research
Smart Beta ETF report for SPYD
Hedge Funds Love These 8 Dividend Blue Chips, And So Should You
07:15am, Tuesday, 07'th Feb 2023
Hedge funds employ some of the world's brightest analysts, with the most resources for analyzing companies. Lists of the most widely owned blue-chips among hedge funds can be a good source of new inve
Is Biotech Immunocore About To Make A 25% Price Move?
07:00am, Tuesday, 07'th Feb 2023
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc
Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod
06:27pm, Monday, 06'th Feb 2023 Zacks Investment Research
Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult pat
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
03:30pm, Monday, 06'th Feb 2023 Zacks Investment Research
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod
03:03pm, Monday, 06'th Feb 2023
Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult pat
Is Gilead Sciences a Good Stock to Buy Now?
10:41am, Monday, 06'th Feb 2023 The Motley Fool
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.
Is Gilead Sciences a Good Stock to Buy Now?
05:41am, Monday, 06'th Feb 2023
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.
GILD Stock: 3.82% Stock Increase Explained
12:16am, Sunday, 05'th Feb 2023
The stock price of Gilead Sciences (NASDAQ: GILD) increased by 3.82% in the most recent trading session. This is why.
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
09:16pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
